FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2477897130> ?p ?o ?g. }

• W2477897130 endingPage "3011" @default.
• W2477897130 startingPage "3011" @default.
• W2477897130 abstract "3011 Background: Outcomes are poor for patients (pts) with recurrent/metastatic (R/M) SCCHN, and new treatments are needed. An ongoing phase I/II, multicenter, open-label study (NCT01693562) is evaluating the safety and efficacy of MEDI4736 (M), a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity, in multiple solid tumor types including SCCHN. PD-L1 is expressed in SCCHN tumors and may be associated with response to anti-PD-L1 treatment. Methods: Pts with R/M SCCHN, an ECOG of 0 or 1, without prior anti-PD-1/PD-L1 exposure are eligible. M is administered IV every 2 weeks at 10 mg/kg for 12 months. Retreatment is permitted upon progression after 12 months. PD-L1 expression is assessed by IHC using the Ventana SP263 clone. Prior documented HPV status is collected at study entry. Response is based on investigator assessment per RECIST v1.1. Data included represent a larger population with more mature follow up than previously reported (Fury M, et al. Poster presented at ESMO 2014, 988PD). Results: As of 31 Oct 2014, 62 pts (mean age 58 years [range 24–96]; 86% male; 64% current/prior smokers; ECOG 0/1: 38%/62%; HPV pos/neg/unk: 40%/39%/21%), with a median of 3 prior systemic treatments (1–10), received a median of 6 doses (1–26). Drug-related AEs were observed in 60% of pts; the most frequent were fatigue (11%), diarrhea, (8%), and nausea (7%). Grade ≥ 3 related AEs were reported in 7% of pts: rash (2 pts), and increased GGT, fatigue, and tumor inflammation (1 pt each). No drug-related AEs led to discontinuation or death. No colitis or grade ≥ 3 pneumonitis was observed. Overall, 51 pts were evaluable for response with ≥ 24 weeks of follow up; ORR was 12% (25% in PD-L1+ pts), and DCR at 24 weeks was 16% (25% in PD-L1+ pts). Responses are ongoing in 5/6 responding pts, with response durations ranging from 4+ to 43+ weeks. Median duration of response has not been reached. Conclusions: With more mature follow up, the safety profile of M in SCCHN is manageable and consistent with previous reports. Responses are durable; ORR and DCR are higher in PD-L1+ pts. A registration program is underway in pts with SCCHN for M alone and in combination with tremelimumab. Clinical trial information: NCT01693562." @default.
• W2477897130 created "2016-08-23" @default.
• W2477897130 creator A5001771767 @default.
• W2477897130 creator A5008158683 @default.
• W2477897130 creator A5014073173 @default.
• W2477897130 creator A5018401879 @default.
• W2477897130 creator A5021550191 @default.
• W2477897130 creator A5022384270 @default.
• W2477897130 creator A5026861780 @default.
• W2477897130 creator A5028021994 @default.
• W2477897130 creator A5032809504 @default.
• W2477897130 creator A5046273815 @default.
• W2477897130 creator A5052730435 @default.
• W2477897130 creator A5062202820 @default.
• W2477897130 creator A5062235853 @default.
• W2477897130 creator A5072271778 @default.
• W2477897130 creator A5076873642 @default.
• W2477897130 creator A5079738340 @default.
• W2477897130 creator A5087923582 @default.
• W2477897130 creator A5090082356 @default.
• W2477897130 date "2015-05-20" @default.
• W2477897130 modified "2023-10-14" @default.
• W2477897130 title "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort." @default.
• W2477897130 doi "https://doi.org/10.1200/jco.2015.33.15_suppl.3011" @default.
• W2477897130 hasPublicationYear "2015" @default.
• W2477897130 type Work @default.
• W2477897130 sameAs 2477897130 @default.
• W2477897130 citedByCount "42" @default.
• W2477897130 countsByYear W24778971302015 @default.
• W2477897130 countsByYear W24778971302016 @default.
• W2477897130 countsByYear W24778971302017 @default.
• W2477897130 countsByYear W24778971302018 @default.
• W2477897130 countsByYear W24778971302019 @default.
• W2477897130 countsByYear W24778971302020 @default.
• W2477897130 countsByYear W24778971302021 @default.
• W2477897130 countsByYear W24778971302022 @default.
• W2477897130 countsByYear W24778971302023 @default.
• W2477897130 crossrefType "journal-article" @default.
• W2477897130 hasAuthorship W2477897130A5001771767 @default.
• W2477897130 hasAuthorship W2477897130A5008158683 @default.
• W2477897130 hasAuthorship W2477897130A5014073173 @default.
• W2477897130 hasAuthorship W2477897130A5018401879 @default.
• W2477897130 hasAuthorship W2477897130A5021550191 @default.
• W2477897130 hasAuthorship W2477897130A5022384270 @default.
• W2477897130 hasAuthorship W2477897130A5026861780 @default.
• W2477897130 hasAuthorship W2477897130A5028021994 @default.
• W2477897130 hasAuthorship W2477897130A5032809504 @default.
• W2477897130 hasAuthorship W2477897130A5046273815 @default.
• W2477897130 hasAuthorship W2477897130A5052730435 @default.
• W2477897130 hasAuthorship W2477897130A5062202820 @default.
• W2477897130 hasAuthorship W2477897130A5062235853 @default.
• W2477897130 hasAuthorship W2477897130A5072271778 @default.
• W2477897130 hasAuthorship W2477897130A5076873642 @default.
• W2477897130 hasAuthorship W2477897130A5079738340 @default.
• W2477897130 hasAuthorship W2477897130A5087923582 @default.
• W2477897130 hasAuthorship W2477897130A5090082356 @default.
• W2477897130 hasConcept C126322002 @default.
• W2477897130 hasConcept C143998085 @default.
• W2477897130 hasConcept C2780580376 @default.
• W2477897130 hasConcept C2908647359 @default.
• W2477897130 hasConcept C71924100 @default.
• W2477897130 hasConcept C72563966 @default.
• W2477897130 hasConcept C90924648 @default.
• W2477897130 hasConcept C99454951 @default.
• W2477897130 hasConceptScore W2477897130C126322002 @default.
• W2477897130 hasConceptScore W2477897130C143998085 @default.
• W2477897130 hasConceptScore W2477897130C2780580376 @default.
• W2477897130 hasConceptScore W2477897130C2908647359 @default.
• W2477897130 hasConceptScore W2477897130C71924100 @default.
• W2477897130 hasConceptScore W2477897130C72563966 @default.
• W2477897130 hasConceptScore W2477897130C90924648 @default.
• W2477897130 hasConceptScore W2477897130C99454951 @default.
• W2477897130 hasIssue "15_suppl" @default.
• W2477897130 hasLocation W24778971301 @default.
• W2477897130 hasOpenAccess W2477897130 @default.
• W2477897130 hasPrimaryLocation W24778971301 @default.
• W2477897130 hasRelatedWork W2015623938 @default.
• W2477897130 hasRelatedWork W2020107211 @default.
• W2477897130 hasRelatedWork W2315085516 @default.
• W2477897130 hasRelatedWork W2316407790 @default.
• W2477897130 hasRelatedWork W2363890076 @default.
• W2477897130 hasRelatedWork W2376132146 @default.
• W2477897130 hasRelatedWork W2387364079 @default.
• W2477897130 hasRelatedWork W2603773853 @default.
• W2477897130 hasRelatedWork W2964295425 @default.
• W2477897130 hasRelatedWork W3029251336 @default.
• W2477897130 hasVolume "33" @default.
• W2477897130 isParatext "false" @default.
• W2477897130 isRetracted "false" @default.
• W2477897130 magId "2477897130" @default.
• W2477897130 workType "article" @default.